non-small cell lung cancer
Conditions
Interventions
None listed
Sponsors
National Hospital Organization
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed non-small cell lung cancer: Stage I, II, IIIA, or IIIB (T4 or N3) disease Newly diagnosed disease: Must have tumor blocks/slides available and must be willing to provide tissue samples 2. Informed cnosent 3. Information of smoking history 4. Ability to answer questionnaire
Exclusion criteria
Exclusion criteria: 1. Prior chemotherapy or radiotherapy 2. Other prior malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Assess lung tissue from patients with stage I, stage II, stage IIIA, or stage IIIB non-small cell lung cancer for alterations in specific genes, including EGFR, Kras and ALK, and for expression of HER2 and estrogen receptors and for detection of Human Papilloma virus (HPV), and for exploring new molecular markers using a next generation DNA sequencer. 2. Determine whether the frequency of EGFR, Kras and ALK mutations differ in lung cancer between never smokers and ever-smokers males and females. 3. Determine whether the frequency of EGFR mutations is higher in never smokers with exposed long duration of passive smoke than those with short one, divided by the median duration. 4. Determine whether the detection rate of HPV is higher in the southern part region than the northern in Japan. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Determine whether relapse rate, disease free survival and overall survival time differ among the patients with EGFR mutations, Kras and the any other. 2. Determine whether mutational profiles differ between Japanese and Americans adjusting by gender, smoking status and other clinical backgrounds. | — |
Countries
Japan
Contacts
Public ContactTomoya Kawaguchi
National Hospital Organization Kinki-chuo Chest Medical Center Internal Medicine
Outcome results
None listed